Vyne Therapeutics Inc Cash Flow Conversion Efficiency
Vyne Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($27.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vyne Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Vyne Therapeutics Inc from 2015 to 2025. This chart illustrates how Vyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Vyne Therapeutics Inc share price for real-time trading data and today's change.
Vyne Therapeutics Inc Cash Flow Conversion Ratio Explained
Vyne Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyne Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Vyne Therapeutics Inc (VYNE) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asia Economy Daily Co Ltd
KQ:127710
|
0.065x |
|
Simat Technologies Public Company Limited
BK:SIMAT
|
-0.062x |
|
Alpha Exploration Ltd
V:ALEX
|
-0.010x |
|
Sin Heng Chan (Malaya) Bhd
KLSE:4316
|
-0.006x |
|
Accent Resources NL
AU:ACS
|
-0.036x |
|
Onelife Capital Advisors Limited
NSE:ONELIFECAP
|
-0.221x |
|
MDI Energia S.A.
WAR:MDI
|
1.692x |
|
GRITEE Inc
KQ:204020
|
0.076x |
Annual Cash Flow Conversion Efficiency for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Vyne Therapeutics Inc from 2015 to 2025. Review how much free cash does Vyne Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more